A drug approved to treat sickle cell disease has been axed by the government, sparking criticism from campaigners.
The medicine, crizanlizumab, which was rolled out in 2022, was hailed as the first new drug to be introduced in more than 20 years for people living with the blood disease, which mainly affects Black, Asian and ethnic minority heritage groups.
